Harold C. Simmons Comprehensive Cancer Center

Dallas, Texas 75390

2 studies enrolling now · 8 studies all time

What they study most

Acute Myeloid Leukemia, B-cell Non-Hodgkin Lymphoma (B-NHL), Breast Cancer, EBV Related PTCL, NOS, EBV-Positive DLBCL, NOS, EBV-Related Hodgkin Lymphoma, EBV-Related Lymphoproliferative Disorder, EBV-Related Non-Hodgkin Lymphoma, EBV-Related PTLD, Epstein-Barr Virus Associated Lymphoma, Hepatocellular Carcinoma, Locally Advanced or Metastatic Unresectable Urothelial Cancer

Studies at this site

• A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer — Recruiting now
• Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) — Recruiting now
• A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma — Recruiting now
• A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies — Running, not enrolling
• Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread — Completed
• An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas — Stopped early
• Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer — Stopped early
• Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations — Stopped early